Clinical trial GNS561-CL-I-Q-0211
New Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer.
(Old Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary liver cancer)
(Old Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary liver cancer)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Genoscience Pharma |
| EudraCT Identifier | 2017-003585-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03316222 |
| Inclusion criteria | RECIST v1.1 |
| Last update |